Preventing health hazards from exposure to benzidine congener dyes
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Preventing health hazards from exposure to benzidine congener dyes

Filetype[PDF-3.17 MB]


  • English

  • Details:

    • Description:
      "Prevention of health hazards from benzidine congener dyes (BCD) is reviewed. The term BCD is defined as commercial preparations of dyes produced from benzidine (92875), o-tolidine (119937), or o- dianisidine (119904). The similarities among the 82 dyes of this type on the market are noted, and their carcinogenic potential is assessed. The cancer causing potential of the dyes and the parent chemicals of the commercial preparations are noted. The impurities present in BCD are cited as actual or potential carcinogens. The need for protection of workers using the manufactured products, as well as those involved in the manufacture of BCD is stressed. Manufacturing operations in which exposure is especially likely are listed. The potential exposure of cleanup crews and maintenance workers is noted. The use of substitute dyes and the mechanism of exposure are discussed. Personal protective equipment used under the varying exposure conditions is listed. Tests and procedures for evaluating exposures to BCD are outlined and include occupational and exposure history; medical history (especially urinary tract or liver complaints); physical examinations; laboratory tests for liver and kidney function and urinalysis; and medical advice on findings. The availability of NIOSH health hazard evaluations for assessment of hazards from BCD is noted. Trademarks and generic names of BCD by parent chemicals are appended." - NIOSHTIC-2

      NIOSHTIC no. 00133335

      83-105.pdf?id=10.26616/NIOSHPUB83105

    • Document Type:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov